{"product_id":"aod9604-5-mg","title":"AOD9604 | 5 MG","description":"\u003cp dir=\"auto\"\u003e\u003cstrong\u003eAOD-9604\u003c\/strong\u003e (also known as hGH Fragment 177-191 or Tyr-hGH177-191) is a synthetic hexadecapeptide (16-amino-acid fragment) derived from the C-terminal region of human growth hormone (hGH). It was originally developed as an investigational compound to retain the lipolytic (fat-breaking) properties of hGH while avoiding its broader effects on growth, IGF-1 elevation, insulin sensitivity disruption, or other hormonal side effects associated with full-length GH.\u003c\/p\u003e\n\u003cp dir=\"auto\"\u003eAOD-9604 is thought to act by stimulating \u003cstrong\u003elipolysis\u003c\/strong\u003e (breakdown of stored fat) in adipose tissue and inhibiting \u003cstrong\u003elipogenesis\u003c\/strong\u003e (new fat formation), potentially through mechanisms involving beta-3 adrenergic receptor pathways or direct modulation of fat cell metabolism—without significantly impacting GH receptors or systemic growth processes.\u003c\/p\u003e\n\u003cp dir=\"auto\"\u003e\u003cstrong\u003ePotential human benefits\u003c\/strong\u003e (primarily from early-phase clinical trials, preclinical animal models showing fat reduction, and anecdotal reports in wellness, fitness, and metabolic research communities):\u003c\/p\u003e\n\u003cul dir=\"auto\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eTargeted fat loss support\u003c\/strong\u003e — early human trials (e.g., 12-week studies) reported modest weight\/fat reductions (e.g., ~2-3 kg in some cohorts), with animal models demonstrating significant body weight\/fat decreases and increased lipolytic activity in adipose tissue.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImproved body composition\u003c\/strong\u003e — potential for preferential reduction of stubborn fat stores while preserving lean mass, appealing for metabolic optimization or recomposition goals.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMetabolic and energy perks\u003c\/strong\u003e — hints of enhanced fat oxidation, energy expenditure, and metabolic flexibility without adverse effects on glucose tolerance or insulin sensitivity seen with full hGH.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eJoint and cartilage support\u003c\/strong\u003e — some preclinical observations suggest possible benefits for osteoarthritis or bone health via direct effects on osteoblasts or tissue repair pathways.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGeneral wellness advantages\u003c\/strong\u003e — anecdotal accounts often describe better energy levels, reduced fatigue, and support for fat metabolism without appetite changes, cortisol spikes, or other common GH-related disruptions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp dir=\"auto\"\u003eHuman evidence is mixed and limited: initial small trials showed promise for safety\/tolerability and some fat loss, but later Phase 2b studies (including larger cohorts with diet\/exercise controls) failed to demonstrate consistent, significant weight reduction, leading to discontinued development as an obesity drug. No large-scale, confirmatory trials have established efficacy for fat loss or other indications, and benefits remain largely preclinical or self-reported.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e\u003cb\u003eImportant Notice:\u003c\/b\u003e\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eThis product is intended \u003cb\u003efor research use only\u003c\/b\u003e.\u003cbr\u003e\u003cb\u003eNot for human or animal use of any kind.\u003c\/b\u003e\u003cbr\u003e\u003cb\u003eNot a drug. Not approved for clinical or therapeutic use.\u003c\/b\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e","brand":"VANTA PEPTIDES","offers":[{"title":"Default Title","offer_id":52430271447368,"sku":null,"price":59.99,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0943\/0633\/7096\/files\/AOD_9604.jpg?v=1772142143","url":"https:\/\/vanta-peptides.com\/de\/products\/aod9604-5-mg","provider":"VANTA","version":"1.0","type":"link"}